An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Status:	Active, not recruiting
Conditions:	Blood Cancer, Blood Cancer, Hematology, Leukemia
Therapuetic Areas:	Hematology, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	12/6/2018
Start Date:	January 27, 2015
End Date:	September 15, 2021

A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia

The purpose of this study is to determine the safety and effectiveness of ulocuplumab in
combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid
Leukemia (AML).

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Newly Diagnosed Acute Myeloid Leukemia (AML)

- Considered inappropriate for intensive remission induction therapy by an investigator

- Not eligible for stem cell transplantation

Exclusion Criteria:

- Acute promyelocytic leukemia

- Current Myelodysplastic syndrome only subjects

- Unstable angina or uncontrolled congestive heart failure

- Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ
melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial
bladder cancer stage 0, from which the subject has not been disease-free for at least
3 years

- Respiratory disease requiring continuous supplemental oxygen

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

University of Cincinnati

2600 Clifton Ave
Cincinnati, Ohio 45267

(513) 556-6000